NO301284B1 - Fremgangsmåte for fremstilling av et ikke naturlig forekommende pseudorabiesvirus, samt fremgangsmåte for in vitro bestemmelse av hvorvidt et vaksinert dyr er blitt smittet med et virulent pseudorabiesvirus av villtype - Google Patents
Fremgangsmåte for fremstilling av et ikke naturlig forekommende pseudorabiesvirus, samt fremgangsmåte for in vitro bestemmelse av hvorvidt et vaksinert dyr er blitt smittet med et virulent pseudorabiesvirus av villtype Download PDFInfo
- Publication number
- NO301284B1 NO301284B1 NO871313A NO871313A NO301284B1 NO 301284 B1 NO301284 B1 NO 301284B1 NO 871313 A NO871313 A NO 871313A NO 871313 A NO871313 A NO 871313A NO 301284 B1 NO301284 B1 NO 301284B1
- Authority
- NO
- Norway
- Prior art keywords
- virus
- prv
- gene
- fragment
- plasmid
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 114
- 241001465754 Metazoa Species 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 41
- 238000000338 in vitro Methods 0.000 title claims description 3
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims abstract description 94
- 229960005486 vaccine Drugs 0.000 claims abstract description 42
- 238000012217 deletion Methods 0.000 claims abstract description 30
- 230000037430 deletion Effects 0.000 claims abstract description 30
- 210000002966 serum Anatomy 0.000 claims description 15
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 claims description 13
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 claims description 13
- 101710181600 Glycoprotein gp2 Proteins 0.000 claims description 12
- 108020004440 Thymidine kinase Proteins 0.000 claims description 8
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 5
- 108020005202 Viral DNA Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 230000010076 replication Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 50
- 102000003886 Glycoproteins Human genes 0.000 abstract description 11
- 108090000288 Glycoproteins Proteins 0.000 abstract description 11
- 239000000427 antigen Substances 0.000 abstract description 7
- 108091007433 antigens Proteins 0.000 abstract description 7
- 102000036639 antigens Human genes 0.000 abstract description 7
- 230000000405 serological effect Effects 0.000 abstract description 2
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 abstract 1
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 abstract 1
- 229940124841 Herpesvirus vaccine Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 description 80
- 239000013612 plasmid Substances 0.000 description 54
- 241000282887 Suidae Species 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 25
- 101150003725 TK gene Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 241000700584 Simplexvirus Species 0.000 description 16
- 241000282898 Sus scrofa Species 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 238000010276 construction Methods 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 210000004927 skin cell Anatomy 0.000 description 8
- 108091026890 Coding region Proteins 0.000 description 7
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- QHGUCRYDKWKLMG-UHFFFAOYSA-N octopamine Chemical compound NCC(O)C1=CC=C(O)C=C1 QHGUCRYDKWKLMG-UHFFFAOYSA-N 0.000 description 7
- 229960001576 octopamine Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 229960000187 tissue plasminogen activator Drugs 0.000 description 7
- 241000209094 Oryza Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 230000001018 virulence Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 208000009305 pseudorabies Diseases 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- QXGOTKHNSYEDRC-HCWSKCQFSA-N O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(OI)N1C(=O)NC(=O)C=C1 Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(OI)N1C(=O)NC(=O)C=C1 QXGOTKHNSYEDRC-HCWSKCQFSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006542 Bulbar palsy Diseases 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100024071 Dystrobrevin beta Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101800000342 Glycoprotein C Proteins 0.000 description 1
- 241000700328 Herpes simplex virus (type 1 / strain F) Species 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000004135 animal tissue culture Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 108010091889 dendrotoxin B Proteins 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 101150118312 gp63 gene Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000009295 sperm incapacitation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 108091005994 sulfated proteins Proteins 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76013085A | 1985-07-29 | 1985-07-29 | |
PCT/US1986/001322 WO1987000862A1 (en) | 1985-07-29 | 1986-06-17 | Virus vaccine |
Publications (3)
Publication Number | Publication Date |
---|---|
NO871313L NO871313L (no) | 1987-03-27 |
NO871313D0 NO871313D0 (no) | 1987-03-27 |
NO301284B1 true NO301284B1 (no) | 1997-10-06 |
Family
ID=25058182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO871313A NO301284B1 (no) | 1985-07-29 | 1987-03-27 | Fremgangsmåte for fremstilling av et ikke naturlig forekommende pseudorabiesvirus, samt fremgangsmåte for in vitro bestemmelse av hvorvidt et vaksinert dyr er blitt smittet med et virulent pseudorabiesvirus av villtype |
Country Status (18)
Country | Link |
---|---|
US (1) | US4810634A (xx) |
EP (1) | EP0231209B1 (xx) |
JP (2) | JP2559384B2 (xx) |
KR (1) | KR950000887B1 (xx) |
CN (1) | CN1018845B (xx) |
AT (1) | ATE60799T1 (xx) |
AU (1) | AU591145B2 (xx) |
CA (1) | CA1275625C (xx) |
DE (1) | DE3677494D1 (xx) |
DK (1) | DK170948B1 (xx) |
ES (1) | ES2001752A6 (xx) |
FI (1) | FI871362A (xx) |
HK (1) | HK32696A (xx) |
IE (1) | IE59087B1 (xx) |
NO (1) | NO301284B1 (xx) |
PH (1) | PH25776A (xx) |
WO (1) | WO1987000862A1 (xx) |
ZA (1) | ZA865277B (xx) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041536A (en) * | 1984-05-02 | 1991-08-20 | The Upjohn Company | Pseudorabies virus (PRV) gene |
US5128128A (en) * | 1985-07-29 | 1992-07-07 | The Upjohn Company | Virus vaccine |
US5275934A (en) * | 1985-07-29 | 1994-01-04 | The Upjohn Company | Method of detecting viral infection in vaccinated animals |
EP0263207B1 (en) * | 1986-10-08 | 1991-11-27 | The Upjohn Company | Virus vaccine |
US5047237A (en) * | 1985-09-06 | 1991-09-10 | Prutech Research And Development Partnership | Attenuated pseudorabies virus having a deletion of at least a portion of a gene encoding an antigenic, nonessential protein, vaccine containing same and methods of identifying animals vaccinated with the vaccine |
US5068192A (en) * | 1986-01-27 | 1991-11-26 | Prutech Research And Development Partnership | Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence |
US5763269A (en) * | 1985-09-06 | 1998-06-09 | Syntro Corporation | Recombinant infectious bovine rhinotrocheitis virus |
US5352575A (en) * | 1985-10-04 | 1994-10-04 | The Upjohn Company | Pseudorabies virus protein |
EP0238618A1 (en) * | 1985-10-04 | 1987-09-30 | The Upjohn Company | Pseudorabies virus protein |
US6251634B1 (en) | 1985-11-26 | 2001-06-26 | Pharmacia & Upjohn Company | Pseudorabies virus protein |
US5593873A (en) * | 1986-01-27 | 1997-01-14 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
AU623333B2 (en) * | 1986-01-27 | 1992-05-14 | Syntro Corporation | Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same |
FR2601689B1 (fr) * | 1986-07-17 | 1992-10-16 | Syntro Corp | Herpes virus attenues, herpes virus qui renferment de l'adn etranger codant pour une sequence d'amino-acides, et vaccins les contenant |
US5004693A (en) * | 1986-07-18 | 1991-04-02 | E. I. Du Pont De Nemours And Company | Pseudorabies virus recombinants and their use in the production of proteins |
US5037742A (en) * | 1986-07-18 | 1991-08-06 | E. I. Du Pont De Nemours And Company | Pseudorabies virus recombinants and their use in the production of proteins |
WO1988007088A1 (en) * | 1987-03-19 | 1988-09-22 | Synergen, Inc. | Viral vector system for the introduction of foreign dna expression products into gallinaceous birds |
US5273876A (en) * | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
EP0658623A3 (en) * | 1987-07-27 | 1995-09-27 | Syntro Corp | Attenuated herpes viruses, herpes viruses that contain foreign DNA encoding an amino acid sequence, and vaccines containing them. |
US5783195A (en) * | 1991-07-18 | 1998-07-21 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus S-IBR-052 and uses thereof |
US5128129A (en) * | 1987-11-03 | 1992-07-07 | Novagene Inc. | Infectious bovine rhinotrachetis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same |
US4992051A (en) * | 1987-11-03 | 1991-02-12 | Novagene, Inc. | Infectious bovine rhinotracheitis virus mutants, methods for the production of same and methods for the use of same |
US5069901A (en) * | 1988-02-03 | 1991-12-03 | Jones Elaine V | Preparation of a recombinant subunit vaccine against pseudorabies infection |
JP2779447B2 (ja) * | 1988-03-20 | 1998-07-23 | 財団法人阪大微生物病研究会 | 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体 |
JP2583115B2 (ja) * | 1988-09-10 | 1997-02-19 | 財団法人化学及血清療法研究所 | 組換えマレック病ウイルスおよびその製法 |
US5122447A (en) * | 1989-01-23 | 1992-06-16 | Iowa State University Research Foundation, Inc. | Method of detecting pseudorabies virus specific serum antibody by use of a universal diagnostic antigen |
US5240703A (en) * | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
EP0598759A4 (en) * | 1991-07-18 | 1998-06-03 | Syntro Corp | RECOMBINANT VIRUS OF INFECTIOUS RHINE TRACHEITIS OF CATTLE. |
US5874279A (en) * | 1991-07-18 | 1999-02-23 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
WO1993024147A1 (en) * | 1992-05-29 | 1993-12-09 | Smithkline Beecham Corporation | Lecithin adjuvanted modified live virus vaccines |
TW289731B (xx) * | 1992-07-09 | 1996-11-01 | Akzo Nv | |
ES2187508T3 (es) * | 1992-07-30 | 2003-06-16 | Akzo Nobel Nv | Vacunas vectores de herpes virus felino recombinado. |
US5738854A (en) * | 1992-10-06 | 1998-04-14 | Akzo Nobel N.V. | Pseudorabies virus vaccine |
WO1994008000A1 (en) * | 1992-10-06 | 1994-04-14 | Akzo Nobel N.V. | Pseudorabies virus vaccine |
ES2074965B1 (es) * | 1994-01-31 | 1996-05-01 | Hipra Lab Sa | Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen. |
HU220746B1 (hu) * | 1994-06-17 | 2002-05-28 | Instituut Voor Veehouderij En Diergezondheid | Pestivírustörzsekből izolált nukleotidszekvenciák, az általuk kódolt polipeptidek és ezek alkalmazása pestivírus-fertőzések diagnosztizálására és megelőzésére |
US6284251B1 (en) | 1996-02-26 | 2001-09-04 | Kansas State University Research Foundation | BHV-1 gene-deleted virus vaccine |
GB0126047D0 (en) * | 2001-10-30 | 2001-12-19 | Univ Cambridge Tech | Therapeutic molecules |
US10918712B2 (en) | 2014-03-03 | 2021-02-16 | Albert Einstein College Of Medicine | Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors |
CN110938604B (zh) | 2014-03-03 | 2024-04-05 | 阿尔伯特爱因斯坦医学院 | 重组单纯疱疹病毒2(hsv-2)疫苗载体 |
WO2017106736A1 (en) * | 2015-12-18 | 2017-06-22 | Louisiana State University Research & Technology Foundation | Pseudorabies virus (prv) vector expressing heterologous polypeptides |
JP7337921B2 (ja) * | 2018-11-06 | 2023-09-04 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 鳥インフルエンザウイルスh5亜型に対する免疫原性組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
NL8303501A (nl) * | 1983-10-12 | 1985-05-01 | Centraal Diergeneeskundig Inst | Deletiemutant van een herpesvirus en vaccin, dat dit virus bevat. |
US4514497B1 (en) * | 1983-12-30 | 1998-02-24 | Novagene Inc | Modified live pseudorabies viruses |
US4703011A (en) * | 1985-11-12 | 1987-10-27 | Novagene, Inc. | Thymidine kinase deletion mutants of bovine herpesvirus-1 |
US4711850A (en) * | 1986-01-28 | 1987-12-08 | Novagene, Inc. | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same |
-
1986
- 1986-06-17 KR KR1019870700280A patent/KR950000887B1/ko not_active IP Right Cessation
- 1986-06-17 WO PCT/US1986/001322 patent/WO1987000862A1/en active IP Right Grant
- 1986-06-17 EP EP86904022A patent/EP0231209B1/en not_active Expired - Lifetime
- 1986-06-17 AT AT86904022T patent/ATE60799T1/de not_active IP Right Cessation
- 1986-06-17 JP JP61503474A patent/JP2559384B2/ja not_active Expired - Lifetime
- 1986-06-17 DE DE8686904022T patent/DE3677494D1/de not_active Expired - Lifetime
- 1986-06-17 AU AU59948/86A patent/AU591145B2/en not_active Expired
- 1986-06-17 US US07/049,865 patent/US4810634A/en not_active Expired - Lifetime
- 1986-07-11 CA CA000513617A patent/CA1275625C/en not_active Expired - Lifetime
- 1986-07-15 ZA ZA865277A patent/ZA865277B/xx unknown
- 1986-07-23 PH PH34058A patent/PH25776A/en unknown
- 1986-07-28 IE IE199686A patent/IE59087B1/en not_active IP Right Cessation
- 1986-07-28 ES ES8600629A patent/ES2001752A6/es not_active Expired
- 1986-07-29 CN CN86105450A patent/CN1018845B/zh not_active Expired
-
1987
- 1987-03-27 NO NO871313A patent/NO301284B1/no not_active IP Right Cessation
- 1987-03-27 FI FI871362A patent/FI871362A/fi not_active Application Discontinuation
- 1987-03-27 DK DK157087A patent/DK170948B1/da active IP Right Grant
-
1995
- 1995-12-18 JP JP7328734A patent/JP2738524B2/ja not_active Expired - Lifetime
-
1996
- 1996-02-22 HK HK32696A patent/HK32696A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPS63500449A (ja) | 1988-02-18 |
JP2559384B2 (ja) | 1996-12-04 |
PH25776A (en) | 1991-10-18 |
NO871313L (no) | 1987-03-27 |
CA1275625C (en) | 1990-10-30 |
CN1018845B (zh) | 1992-10-28 |
CN86105450A (zh) | 1987-03-04 |
AU5994886A (en) | 1987-03-05 |
IE59087B1 (en) | 1994-01-12 |
KR880700070A (ko) | 1988-02-15 |
DE3677494D1 (de) | 1991-03-14 |
DK170948B1 (da) | 1996-03-25 |
ATE60799T1 (de) | 1991-02-15 |
DK157087A (da) | 1987-03-27 |
EP0231209A1 (en) | 1987-08-12 |
FI871362A0 (fi) | 1987-03-27 |
US4810634A (en) | 1989-03-07 |
ZA865277B (en) | 1987-03-25 |
HK32696A (en) | 1996-03-01 |
JPH08333279A (ja) | 1996-12-17 |
NO871313D0 (no) | 1987-03-27 |
JP2738524B2 (ja) | 1998-04-08 |
WO1987000862A1 (en) | 1987-02-12 |
FI871362A (fi) | 1987-03-27 |
ES2001752A6 (es) | 1988-06-16 |
KR950000887B1 (ko) | 1995-02-03 |
DK157087D0 (da) | 1987-03-27 |
IE861996L (en) | 1987-01-29 |
EP0231209B1 (en) | 1991-02-06 |
AU591145B2 (en) | 1989-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO301284B1 (no) | Fremgangsmåte for fremstilling av et ikke naturlig forekommende pseudorabiesvirus, samt fremgangsmåte for in vitro bestemmelse av hvorvidt et vaksinert dyr er blitt smittet med et virulent pseudorabiesvirus av villtype | |
Van Oirschot et al. | Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease | |
EP0573614B1 (en) | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof | |
Marchioli et al. | Evaluation of pseudorabies virus glycoprotein gp50 as a vaccine for Aujeszky's disease in mice and swine: expression by vaccinia virus and Chinese hamster ovary cells | |
WO1989006972A1 (en) | Preparation of a recombinant subunit vaccine against pseudorabies infection | |
Wathen et al. | Characterization and mapping of a nonessential pseudorabies virus glycoprotein | |
Fitzpatrick et al. | Expression of bovine herpesvirus 1 glycoproteins gI and gIII in transfected murine cells | |
CA1339468C (en) | Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same | |
EP0223382B1 (en) | Pseudorabies virus protein | |
US5352575A (en) | Pseudorabies virus protein | |
El-Kholy et al. | Baculovirus expression and diagnostic utility of the glycoprotein E of bovine herpesvirus-1.1 Egyptian strain “Abu-Hammad” | |
US5275934A (en) | Method of detecting viral infection in vaccinated animals | |
Yan et al. | Better immune efficacy triggered by the inactivated gI/gE-deleted pseudorabies virus with the additional insertion of gC gene in mice and weaned pigs | |
US6172186B1 (en) | Pseudorabies virus protein | |
KR20030032914A (ko) | Gm-음성 ehv-돌연변이 | |
US5128128A (en) | Virus vaccine | |
EP0263207B1 (en) | Virus vaccine | |
US6261563B1 (en) | Pseudorabies virus protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1K | Patent expired |